Common questions about Symbyax (FAQ)
Q: Are there any over-the-counter pain relievers that interact with Symbyax?
A: Official labeling advises caution regarding the use of Symbyax with certain over-the-counter pain relievers, specifically non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin. This is because these agents may increase the potential for bleeding or bruising when taken together.
Q: Does Symbyax increase the risk of bleeding or bruising?
A: Regulatory information indicates that Symbyax may increase the risk of bleeding or bruising, especially when it is taken along with other specific medications that affect blood clotting. These interacting medicines include agents like NSAIDs, aspirin, and warfarin.
Q: Are there specific medical conditions that make a person ineligible to take Symbyax?
A: Regulatory documents define specific criteria for who should not take this medication. Symbyax is strictly contraindicated for anyone with a known allergy to its components (olanzapine or fluoxetine). It is also forbidden for patients who are currently taking a Monoamine Oxidase Inhibitor (MAOI) or medicines like pimozide or thioridazine.
Q: Is Symbyax safe to use while breastfeeding?
A: Official regulatory bodies state that breastfeeding is generally not recommended while a person is undergoing treatment with Symbyax. This is due to the potential for the active components of the medication to pass into breast milk.
Q: Does Symbyax affect blood sugar or cholesterol levels?
A: Yes, Symbyax is associated with changes in metabolic parameters. These changes can include elevated blood glucose (sugar) and increases in blood levels of cholesterol and triglycerides, and monitoring for these changes may be part of treatment.
Q: Can Symbyax interact with herbal supplements like St. John's wort?
A: The FDA does not recommend the co-administration of Symbyax with herbal supplements like St. John's wort. This is due to the potential for increased serotonergic activity, which raises the risk of a severe condition known as Serotonin Syndrome.
Q: Does the fluoxetine component in Symbyax increase the risk of Serotonin Syndrome?
A: Yes, because the fluoxetine component is classified as a serotonergic drug, there is a serious, documented risk of Serotonin Syndrome. This risk is particularly noted when Symbyax is taken alongside other medicines or supplements that increase serotonin levels.
Q: What is the difference between Symbyax and taking olanzapine and fluoxetine separately?
A: Symbyax is distinct because it is a fixed-dose capsule, ensuring that both active agents are taken simultaneously. While regulatory studies suggest that the overall steady-state concentrations of the drugs in the blood are comparable to taking them separately, the combination formulation affects the metabolism of the olanzapine component.
Q: Is Symbyax used to treat general anxiety?
A: The medication is only approved by the FDA for its specific, studied indications. These approved uses are strictly limited to treating depressive episodes associated with Bipolar I Disorder and Major Depressive Disorder that is defined as Treatment-Resistant Depression (TRD).
Q: What foods or drinks should be avoided while taking Symbyax?
A: Official labeling advises against the use of alcohol because it may increase the risk of side effects like sedation and low blood pressure. The capsules are typically taken by mouth with or without food, as indicated in the administration instructions.
Q: Does smoking tobacco affect how Symbyax works?
A: Yes, smoking tobacco can affect the metabolism of the olanzapine component in the medication. Regulatory information indicates that tobacco smoke can induce CYP1A2 activity, which may result in an increased clearance of olanzapine from the body.
Q: Can I switch from a different antidepressant to Symbyax without a waiting period?
A: Switching from a certain class of medications requires a strict waiting period to avoid serious drug interactions. Specifically, switching from a Monoamine Oxidase Inhibitor (MAOI) to Symbyax requires a mandatory washout period of at least 14 days before starting treatment.
Q: Why is Symbyax sometimes used for depression that is "treatment-resistant"?
A: Symbyax is approved for this use because the combination provides a dual neurochemical action not available in a single agent. This mechanism leverages fluoxetine's targeted serotonin activity alongside olanzapine's wider modulation of neuroreceptors, including dopamine.
Q: Is Symbyax a controlled substance or narcotic?
A: Symbyax is a medication that requires a prescription from a licensed healthcare provider. However, it is not listed or classified as a federally controlled substance or narcotic in the United States.
Q: Is the Olanzapine component in Symbyax the same as Zyprexa?
A: Yes, the olanzapine component found in Symbyax is the same active ingredient found in the monotherapy medication Zyprexa. The fixed-dose capsule simply combines this agent with fluoxetine hydrochloride.
Q: How is Symbyax different from a typical SSRI drug?
A: A typical Selective Serotonin Reuptake Inhibitor (SSRI) primarily works by affecting serotonin levels alone. Symbyax is different because it is a combination that includes an SSRI (fluoxetine) and also an atypical antipsychotic (olanzapine), which modulates multiple neuroreceptors, including dopamine.
Q: Do all dosage strengths of Symbyax contain the same ratio of the two active ingredients?
A: No, the ratio of the two active ingredients is not constant across all available strengths of the medication. The various capsule strengths contain different amounts of olanzapine and fluoxetine to allow for specific adjustment options.
Q: Can Symbyax be used to prevent manic episodes?
A: The regulatory indication for Symbyax is the acute treatment of depressive episodes associated with Bipolar I Disorder. The medication is not specifically approved by regulatory bodies for the long-term prevention of manic episodes.
Q: What are the long-term metabolic risks associated with Symbyax use?
A: Long-term use of the medication is associated with metabolic changes that carry specific risks. These risks include the potential for sustained weight gain, high blood sugar (hyperglycemia), and increased levels of cholesterol and triglycerides (hyperlipidemia).
Q: Can Symbyax cause a feeling of restlessness or 'jitters'?
A: Restlessness, or the inability to sit still, is a reported side effect known as akathisia. This effect is associated with the atypical antipsychotic (olanzapine) component of the medication.
Q: What is the relationship between Symbyax and low blood pressure or dizziness?
A: Low blood pressure, specifically a condition called orthostatic hypotension, is a commonly reported side effect. This drop in blood pressure often happens when a person stands up and can lead to feelings of dizziness, especially when initiating treatment.
Q: Can Symbyax affect body temperature regulation?
A: A potentially fatal symptom complex called Neuroleptic Malignant Syndrome (NMS) is a documented risk associated with the olanzapine component. NMS includes severe changes in body temperature, such as hyperpyrexia (high fever).
Q: Are there specific organs, such as the liver, that need to be monitored during Symbyax treatment?
A: Yes, the FDA labeling notes that increased liver transaminases, which are indicators of liver function, are a common side effect. Furthermore, official labeling indicates that a lower starting dose may be considered for patients with documented hepatic impairment, suggesting the liver is a focus of monitoring.
Q: What serious symptoms are associated with the condition known as Neuroleptic Malignant Syndrome (NMS) with Symbyax?
A: Clinical manifestations of Neuroleptic Malignant Syndrome (NMS) are detailed in the official warnings. Key symptoms include a high fever (hyperpyrexia), severe muscle stiffness (rigidity), a significant change in mental status, and evidence of unstable automatic body functions, such as irregular pulse or blood pressure.
